These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24726509)

  • 1. Systematic review of factors affecting pharmaceutical expenditures.
    Mousnad MA; Shafie AA; Ibrahim MI
    Health Policy; 2014 Jun; 116(2-3):137-46. PubMed ID: 24726509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressants in Brazil: underlying drivers of spending trends, 2010-2015.
    Alves JC; Osorio-de-Castro CGS; Wettermark B; Luz TCB
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):565-572. PubMed ID: 29869896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Health Policy Changes on Trends in the Pharmaceutical Market in Turkey.
    Yılmaz ES; Koçkaya G; Yenilmez FB; Saylan M; Tatar M; Akbulat A; Gürsöz H; Kerman S
    Value Health Reg Issues; 2016 Sep; 10():48-52. PubMed ID: 27881277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceuticals in U.S. health care: determinants of quantity and price.
    Berndt ER
    J Econ Perspect; 2002; 16(4):45-66. PubMed ID: 15179978
    [No Abstract]   [Full Text] [Related]  

  • 7. Prescription drug spending: contribution to health care spending and cost containment strategies.
    Rivers PA; Hall NG; Frimpong J
    J Health Care Finance; 2006; 32(3):8-19. PubMed ID: 18975728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents.
    Kwon HY; Hong JM; Godman B; Yang BM
    Health Policy; 2013 Oct; 112(3):217-26. PubMed ID: 24075008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of the pharmaceutical expenditure in Hungary].
    Inotai A; Merész G; Kaló Z
    Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National trends in prescription drug expenditures and projections for 2024.
    Tichy EM; Hoffman JM; Tadrous M; Rim MH; Cuellar S; Clark JS; Newell MK; Schumock GT
    Am J Health Syst Pharm; 2024 Jul; 81(14):583-598. PubMed ID: 38656319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in prescription drug expenditures by Medicaid enrollees.
    Banthin JS; Miller GE
    Med Care; 2006 May; 44(5 Suppl):I27-35. PubMed ID: 16625061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health expenditure growth: looking beyond the average through decomposition of the full distribution.
    de Meijer C; O'Donnell O; Koopmanschap M; van Doorslaer E
    J Health Econ; 2013 Jan; 32(1):88-105. PubMed ID: 23202257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decade of growth in public and private pharmaceutical expenditures: the case of Belgium 1990-1999.
    Vander Stichele RH; Peys F; Van Tielen R; Van Eeckhout H; van Essche O; Seys B
    Acta Clin Belg; 2003; 58(5):279-89; discussion 277-8. PubMed ID: 14748094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Projecting future drug expenditures--2010.
    Hoffman JM; Doloresco F; Vermeulen LC; Shah ND; Matusiak L; Hunkler RJ; Schumock GT
    Am J Health Syst Pharm; 2010 Jun; 67(11):919-28. PubMed ID: 20484216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Prescription Drug Spending Leading Up to Health Reform.
    Blavin F; Waidmann T; Blumberg LJ; Roth J
    Med Care Res Rev; 2014 Aug; 71(4):416-32. PubMed ID: 24830379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projecting future drug expenditures: 2011.
    Doloresco F; Fominaya C; Schumock GT; Vermeulen LC; Matusiak L; Hunkler RJ; Shah ND; Hoffman JM
    Am J Health Syst Pharm; 2011 May; 68(10):921-32. PubMed ID: 21546644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kaura S
    Health Aff (Millwood); 2016 Sep; 35(9):1588-94. PubMed ID: 27605637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projecting future drug expenditures--2009.
    Hoffman JM; Shah ND; Vermeulen LC; Doloresco F; Martin PK; Blake S; Matusiak L; Hunkler RJ; Schumock GT
    Am J Health Syst Pharm; 2009 Feb; 66(3):237-57. PubMed ID: 19179637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of pharmaceutical policy measures: an endogenous structural-break approach.
    Barros PP; Nunes LC
    Soc Sci Med; 2010 Aug; 71(3):440-450. PubMed ID: 20621744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National trends in prescription drug expenditures and projections for 2023.
    Tichy EM; Hoffman JM; Tadrous M; Rim MH; Suda KJ; Cuellar S; Clark JS; Newell MK; Schumock GT
    Am J Health Syst Pharm; 2023 Jul; 80(14):899-913. PubMed ID: 37094296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.